Phase IIA Open-Label, to Evaluate the Safety, Tolerability, and Efficacy Trend of SCI -110 in Patients With AD and Agitation
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Adverse Events
研究概览
简要总结
As of today, there is no FDA-approved treatment for agitation in AD. Hence, it is still considered an unmet need.
Sporadic observation in healthy or diagnosed individuals indicated that cannabis products, in particular, THC have calming and anti-anxiety effects. These observations are supported by basic science data as well as animal experiments.
SCI -110 is a combination of (1) dronabinol, the active ingredient in an FDA-approved synthetic analog of tetrahydrocannabinol, the psychoactive molecule in the cannabis plant, and (2) palmitoylethanolamide.
In the present study, the starting daily dose for all subjects is 2.5 mg dronabinol and 800 mg PEA and will be gradually increased (every 3 days an addition of 2.5 mg dronabinol per day, with no change in the PEA dose) to a maximum of 12.5 mg Dronebinol and 800 mg PEA per day. The study product will be given orally, twice daily, to add-on the medical treatment.
Study Duration per patient is up to 64 days: a. screening (3-21 days); b. treatment phase: (1) titration (15-23 days) of dronabinol from 2.5 to 12.5 mg or up to the maximal subject's tolerated dose (2) Stabilization phase (10 days) until end of treatment on the highest subject's daily tolerated dose. c. follow-up phase (7 days) - until the end-of-study.
During the study, the tolerability of the drug, its safety (vital signs, physical examinations, blood, and urine tests and side effects follow-up) as well as changes in subject's condition (using CMAI, MMSE, SIB-8 questionnaires), appetite and sleep quality (SDI) will be followed.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 60 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female aged >60 to <85 years inclusive.
- •Patients diagnosed according to the NINCDS criteria for AD (possible and probable).
- •MMSE less than 24 at the time of screening.
- •Patients who in the opinion of the investigators need medication to control agitation or whose current anti-agitation medication is ineffective or poorly tolerated
- •Patients who have been taking stable dose concomitant medications for at least 1 week.
- •Only individuals who have a legally appointed guardian who can sign Informed Consent Form (ICF)
排除标准
- •Participant in other clinical trial during the last 30 days.
- •Any disorder which in the investigator's opinion might jeopardize subject's safety or compliance with the protocol.
- •Patients whose agitation can be attributed to a somatic disorder (Ex. urinary tract infection or urinary retention)
- •Patient with uncontrolled congestive heart failure.
- •Patients who get the following medications: opiates, Primidone, Phenobarbitol, carbamazepine, Rifampicin, Rifabutin, Troglitazone and Hypericum perforatum.
- •Male patients who in the opinion of the investigator are at risk of urinary retention due to the anticholinergic proprieties of THC
- •Subjects with known sensitivity to the active substance dronabinol or to any of the components of the drug (sesame oil, gelatin, glycerol, titanium dioxide
- •Subjects that previously suffered from cannabinoids' related adverse effects.
- •Subjects with a history of diagnosed Mental or Psychiatric diseases
- •Patients who in the opinion of the investigator are at risk of falling beyond the risk associated with AD (example: postural hypotension, unstable blood pressure, with or without administration of anti-hypertensive medication, α1 blocker drugs used to treat benign prostatic hyperplasia
- •Patients diagnosed with epilepsy
研究组 & 干预措施
SCI -110
SCI -110 (Previously known as THX-110): a combination of THC (Doses: 2.5 mg - 12.5 mg per daily dose) and PEA (Dose: 800 mg per daily dose), administered together as separate pills, orally, twice daily (morning and evening - except for the initial titration dose, of 2.5 mg THC+800 mg PEA given once a day, in the morning.
干预措施: SCI -110 (Drug)
结局指标
主要结局
Adverse Events
时间窗: up to 64 days
Number of study treatment (SCI -110) related Adverse Events (AEs) from Baseline (visit 2, day 1) to end of treatment.
drop-out's
时间窗: up to 64 days
Number of drop-out subjects' due to poor tolerability
次要结局
- Change in the Cohen Mansfield Agitation Inventory (CMAI).(up to 64 days)
- Change in Mini Mental State Exam (MMSE)(up to 64 days)
- Change in Sleep Disorders Inventory(up to 64 days)
- Change in cognitive measures from Baseline (visit 2, day 1) to end of treatment measured in SIB-8 8-item Severe Impairment Battery(up to 64 days)
- Change in The Edinburgh Feeding Evaluation in Dementia Scale(up to 64 days)
- rescue medication(up to 64 days)
研究者
dr. Alexander Kaplan
Principal Investigator
The Israeli Medical Center for Alzheimer's